Your browser doesn't support javascript.
loading
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
van Dorp, Jeroen; Pipinikas, Christodoulos; Suelmann, Britt B M; Mehra, Niven; van Dijk, Nick; Marsico, Giovanni; van Montfoort, Maurits L; Hackinger, Sophie; Braaf, Linde M; Amarante, Tauanne; van Steenis, Charlaine; McLay, Kirsten; Daletzakis, Antonios; van den Broek, Daan; van de Kamp, Maaike W; Hendricksen, Kees; de Feijter, Jeantine M; Boellaard, Thierry N; Meijer, Richard P; van der Heijden, Antoine G; Rosenfeld, Nitzan; van Rhijn, Bas W G; Jones, Greg; van der Heijden, Michiel S.
Afiliação
  • van Dorp J; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Pipinikas C; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.
  • Suelmann BBM; Inivata Ltd., Babraham Research Park, Cambridge, UK.
  • Mehra N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.
  • van Dijk N; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Marsico G; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.
  • van Montfoort ML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Hackinger S; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.
  • Braaf LM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Amarante T; Inivata Ltd., Babraham Research Park, Cambridge, UK.
  • van Steenis C; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.
  • McLay K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Daletzakis A; Inivata Ltd., Babraham Research Park, Cambridge, UK.
  • van den Broek D; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van de Kamp MW; Inivata Ltd., Babraham Research Park, Cambridge, UK.
  • Hendricksen K; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Feijter JM; Inivata Ltd., Babraham Research Park, Cambridge, UK.
  • Boellaard TN; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Meijer RP; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Heijden AG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.
  • Rosenfeld N; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Rhijn BWG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.
  • Jones G; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Heijden MS; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.
Nat Med ; 29(3): 588-592, 2023 03.
Article em En | MEDLINE | ID: mdl-36732628
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nivolumabe / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nivolumabe / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article